The Public engagement project on community control measures for pandemic influenza: findings and recommendations from citizen and stakeholder deliberation days

"The Public Engagement Project On Community Control Measures for Pandemic Influenza was carried out in October and November 2006 to engage the public in discussions and deliberations about the economic and social tradeoffs associated with community control measures to slow the spread of the disease. The project was sponsored by the Association of State and Territorial Health Officials (ASTHO) and The Keystone Center, serving as a third party neutral facilitator. Fourteen other organizations participated, including the Centers for Disease Control and Prevention (CDC). To conduct this public engagement, the sponsors made use made use of the Policy Analysis CollaborativE (PACE), an innovative model for engaging both the organized stakeholder public and the general public made up of citizens-at-large." - p. 3Executive summary -- Chapter 1: background -- Chapter 2: Methods for citizen and stakeholder deliberations -- Chapter 3: results -- Section A: on control measures -- Section B: recommendations on implementation -- Chapter 4: summary and consclusions from the overall project -- Appendix A: list of participants for national stakeholder meeting -- Appendix B: evaluation report of the public engagement project on community control measures for pandemic influenza, university of nebraska public policy center.Cover title."May 2007."Also available via the World Wide Web.System requirements: Adobe Acrobat Reader

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

BACKGROUND: To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA). METHODS: This randomized, double-blind phase III study ( ClinicalTrials.gov , NCT03789292) randomized (1:1) subjects with active RA at 52 centers to receive CT-P17 or EU-adalimumab 40 mg subcutaneously every 2 weeks until week 52. Results to week 24 are reported here. The primary endpoint was 20% improvement by American College of Rheumatology criteria (ACR20) response rate at week 24. Equivalence was concluded if the corresponding confidence intervals (CIs) for the estimate of treatment difference were within predefined equivalence margins: - 15 to 15% (95% CI; European Medicines Agency assumption); - 12 to 15% (90% CI; Food and Drug Administration assumption). Additional efficacy, pharmacokinetic, usability, safety, and immunogenicity endpoints were evaluated. RESULTS: 648 subjects were randomized (324 CT-P17; 324 EU-adalimumab). The ACR20 response rate at week 24 was 82.7% (n = 268/324) in both groups (intention-to-treat population). The 95% CI (- 5.94 to 5.94) and 90% CI (- 4.98 to 4.98) were within predefined equivalence margins for both assumptions and equivalent efficacy was concluded. Additional endpoints and overall safety were comparable between groups. Mean trough serum concentrations of CT-P17 were slightly higher than those of EU-adalimumab. Immunogenicity was slightly lower numerically for the CT-P17 group than for the EU-adalimumab group. CONCLUSIONS: CT-P17 and EU-adalimumab have equivalent efficacy and comparable safety and immunogenicity in subjects with active RA. Overall safety of CT-P17 is consistent with the known safety profile of reference adalimumab. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03789292 . Registered 28 December 2018-retrospectively registered

A role for combined vaccination against hepatitis A and B?

AbstractThis report reviews hepatitis A and B immunization recommendations and assesses the potential role of a combined hepatitis vaccine. Although hepatitis A and B are very different diseases, overlap exists in their epidemiologic patterns. Both are most prevalent in developing countries, with areas of low endemicity in industrialized nations. Potential sources of infection common to both hepatitis A and hepatitis B (i.e., international travel, close contact with residents of institutions or young children and infants, male homosexual activity, and drug use) indicate that certain groups may be at increased risk of both diseases. Well-tolerated and immunogenic vaccines are available for both hepatitis A and hepatitis B. Although hepatitis B vaccine is now being introduced into universal infant immunization programs in many countries, hepatitis A vaccination is currently recommended for high-risk groups only. This review examines the potential role of a single vaccination against both forms of hepatitis

Failure of combined chloroquine and High-Dose primaquine therapy for plasmodium vivax malaria acquired in Guyana, South America

The presence of chloroquine-resistant Plasmodium vivax malaria in the New World has been suspected but not confirmed. We report the cases of three patients who acquired vivax malaria in Guyana, South America, and for whom standard chloroquine therapy (25 mg/kg) failed despite therapeutic blood levels. The optimal treatment of chloroquine-resistant P. vivax malaria is unknown, but recent studies suggest that a combination of chloroquine (25 mg/kg) and high-dose primaquine (2.5 mg/kg over 48 hours) is effective therapy. Two of our patients had recurrences of P. vivax malaria 6–8 weeks after receiving directly observed therapy with this combination. These cases confirm the presence of chloroquine-resistant P. vivax in Guyana and emphasize the need for better treatment regimens for chloroquine-resistant and primaquine-resistant P. vivax malaria

Sew on your own buttons, I\u27m going for a ride.

The stereograph features a black and white image of a woman standing holding out an article of clothing toward a man and female child. The man (who wears an apron and holds a broom) and child sit side-by-side looking at the woman. The image is mounted on a cream card with rounded corners.https://scholarsjunction.msstate.edu/fvw-photographs/1249/thumbnail.jp

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

Objectives: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. Methods: In this phase III study, patients were randomised 1:1:1 to placebo (N=228), baricitinib 2 mg once daily (QD, N=229) or baricitinib 4 mg QD (N=227). PROs included the Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, measures from patient electronic daily diaries (duration and severity of morning joint stiffness (MJS), Worst Tiredness, Worst Joint Pain), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), SF-36, EuroQol 5-D index scores and visual analogue scales (VAS) and the Work Productivity and Activity Impairment Questionnaire-RA. The primary time point for the study was week 12. Treatment comparisons were assessed with logistic regression for categorical measures and analysis of covariance for continuous variables. Results: Statistically significant improvements were observed for both baricitinib groups versus placebo in HAQ-DI, PtGA, pain, daily diary measures, EuroQoL index scores and SF-36 physical component score at week 12 and for those measures when assessed at week 24. Baricitinib 2 mg and baricitinib 4 mg were statistically significantly improved versus placebo for the EuroQoL VAS and FACIT-F, respectively, at week 24. Conclusions: Baricitinib 2 or 4 mg provided significant improvement versus placebo in PROs across different domains of RA, including physical function, MJS, fatigue, pain and quality of life

Oslo plenary session : final consensus report; Global Initiative for the Security and Sustainable Use of Plant Genetic Resources

Third Plenary Session, 31 May- 4 June 1991, Oslo, Norwa